EMCURE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | EMCURE | Market Cap | 31,853 Cr. | Current Price | 1,680 ₹ | High / Low | 1,770 ₹ |
| Stock P/E | 47.9 | Book Value | 170 ₹ | Dividend Yield | 0.18 % | ROCE | 13.5 % |
| ROE | 11.6 % | Face Value | 10.0 ₹ | DMA 50 | 1,564 ₹ | DMA 200 | 1,447 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.00 % | PAT Qtr | 282 Cr. | PAT Prev Qtr | 118 Cr. |
| RSI | 59.2 | MACD | 34.7 | Volume | 2,91,097 | Avg Vol 1Wk | 5,65,206 |
| Low price | 950 ₹ | High price | 1,770 ₹ | PEG Ratio | -3.54 | Debt to equity | 0.50 |
| 52w Index | 89.0 % | Qtr Profit Var | 462 % | EPS | 33.7 ₹ | Industry PE | 30.1 |
Financials & Valuation:
EMCURE shows moderate fundamentals. ROCE (13.5%) and ROE (11.6%) are below ideal levels, indicating average efficiency. EPS of 33.7 ₹ supports profitability, and quarterly PAT surged to 282 Cr. from 118 Cr., reflecting strong earnings momentum. Debt-to-equity at 0.50 is relatively high compared to peers, adding leverage risk.
Valuation Indicators:
P/E ratio of 47.9 is significantly higher than the industry average (30.1), suggesting overvaluation. Book Value of 170 ₹ compared to current price of 1,680 ₹ shows premium pricing. PEG ratio of -3.54 indicates valuation concerns relative to growth. Dividend yield of 0.18% is minimal, offering little income support.
Business Model & Health:
EMCURE, a pharmaceutical company, benefits from strong demand in generics and specialty drugs. While profitability momentum is positive, moderate return metrics and higher debt reduce competitive strength. FII holdings declined (-0.24%), showing reduced foreign confidence, while DII holdings remained unchanged.
Entry Zone & Holding Guidance:
Technically, support lies around 1,630–1,650 ₹, with resistance near 1,700–1,720 ₹. Entry near support levels is favorable for swing trades. Long-term holding should be cautious until valuation aligns with industry benchmarks and debt levels improve.
Positive
- Strong quarterly PAT growth (282 Cr. vs 118 Cr.).
- EPS of 33.7 ₹ supports profitability.
- Price above 50 DMA and 200 DMA, showing bullish momentum.
- MACD (34.7) indicates positive technical strength.
Limitation
- High P/E (47.9) vs industry average (30.1).
- PEG ratio (-3.54) reflects valuation concerns.
- ROE (11.6%) and ROCE (13.5%) are moderate.
- Debt-to-equity (0.50) is relatively high.
Company Negative News
- Decline in FII holdings (-0.24%).
- Valuation premium compared to peers.
- Moderate return metrics despite strong PAT growth.
Company Positive News
- Quarterly PAT surged significantly.
- EPS remains positive at 33.7 ₹.
- Technical indicators show bullish momentum.
Industry
- Pharma sector benefits from consistent demand and export opportunities.
- Industry PE (30.1) is lower than EMCURE’s, highlighting overvaluation.
- Long-term growth supported by healthcare demand and innovation.
Conclusion
EMCURE shows strong earnings momentum but faces valuation concerns and moderate efficiency metrics. Entry near 1,630–1,650 ₹ offers a favorable swing trade setup. Long-term investors should be cautious, monitoring debt levels and valuation relative to peers before committing to extended holding.
Would you like me to extend this into a sector overlay comparison against peers like Cipla, Sun Pharma, and Dr. Reddy’s to highlight EMCURE’s relative positioning in profitability and valuation?